MMP9 is an essential factor of selectively modulating the tumor microenvironment and promoting tumor cell development as an inducer of EMT 44, bringing to light that modulation of activity of SLPI may be therapeutically relevant in ovarian cancer, especially influencing metastasis. This evidence concerns the gene SLPI and neoplasm.